阿立哌唑不同晶型的制备、表征及溶解特性研究

目的： 系统地研究阿立哌唑多晶型现象。方法： 采用冷却析晶法、快速去溶剂法和双溶媒析晶法等制备阿立哌唑结晶产物，应用粉末X-射线衍射（PXRD）、差示扫描量热（DSC）、偏光显微镜及傅里叶变换红外光谱等方法对不同晶型进行表征和归属，并通过溶出度实验比较不同晶型的溶解性差异。结果： 本研究制备了阿立哌唑的5种结晶产物，通过与相关专利数据对比进行归属，分别为晶型α、晶型Ⅰ、晶型Ⅲ、晶型Ⅳ、新晶型。不同晶型溶解性差异较大，5种晶型在水中的累积溶出度从高到低依次为新晶型、晶型Ⅲ、晶型α、晶型Ⅰ、晶型Ⅳ，在0.1 mol·L^-1盐酸溶液中的累积溶出度从高到低依次为晶型Ⅰ、晶型α、新晶型、晶型Ⅲ、晶型Ⅳ。结论： 该研究数据为阿立哌唑晶型的质量控制提供了科学依据；所制备的新晶型有较好的溶解性，具有良好的应用和开发前景。

Objective: To study systematically on polymorphism of aripiprazole. Methods: The recrystallization products of aripiprazole were prepared by cooling crystallization method,rapid solvent removal method and double-solvent crystallization method,respectively. The different crystalline forms were characterized and attributed by powder X-ray diffraction(PXRD),differential scanning calorimetry(DSC),polarizing microscope and Fourier transform infrared spectroscopy(FTIR). The solubility properties of different crystalline forms were compared by dissolution experiments. Results: In this study,five recrystallization products of aripiprazole were prepared and assigned by comparing with relevant patent data,as crystal form α,form Ⅰ,form Ⅲ,form Ⅳ and new form respectively. The solubility of different crystalline forms was quite different. The cumulative dissolution rates of five crystal forms in water from high to low were as follows:new form,formⅢ,form α,formⅠ,formⅣ,and in 0.1 mol·L^-1 hydrochloric acid as follows:formⅠ,form α,new form,form Ⅲ,form Ⅳ. Conclusion: The data provide a scientific basis for the crystal quality control of aripiprazole. The new crystals have good solubility,with a good application and development prospects.

[1] AIHARA K,SHIMADA J,MIWA T,et al.The novel antipsychotic aripirazole is a partial agonist at short and long isoforms of D₂ receptors linked to the regulation of adenylyl cyclase activity and prolactin release[J].Brain Res,2004,10(3):9
[2] 朱紫青,张明园.第3代抗精神病药阿立哌唑研究进展[J].中国医院用药评价与分析,2005,5(2):121 ZHU ZQ,ZHANG MY.Advances in the research of the third generation antipsychotic drug aripiprazole[J].Eval Anal Drug Use Hosp China,2005,5(2):121
[3] 郑广翔,徐淼.从阿立哌唑的药理学特性看其疗效和副作用[J].精神疾病与精神卫生,2008,8(6):487 ZHENG GX,XU M.Therapeutic effect and side effects of aripiprazole from its pharmacological characteristics[J].Nerv Dis Ment Health,2008,8(6):487
[4] TACHIBANA T,KATO M,TAKANO J,et al.Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein[J].Curr Drug Metab,2010,11(9):762
[5] 杨亮蕊,陈旭冰,陈光勇,等.阿立哌唑的研究状态[J].中国医药指南,2010,6(8):75 YANG LR,CHEN XB,CHEN GY,et al.Research status of aripiprazole[J].Guide China Med,2010,6(8):75
[6] BOURIN M,AUBY P,SWANINK R,et al.Aripiprazole versus haloperidol for maintained treatment effect in acute mania[M]//New Research Abstracts of the 156th Annual Meeting of the American Psychiatric Association.San Francisco,Calif.2003-05-20,Abstract NR467:175
[7] 唐素芳.药物多晶型的研究及其对药效和理化性质的影响[J].天津药学,2002,14(2):12 TANG SF.Study on polymorphism of drugs and its effect on pharmacodynamics and physicochemical properties[J].Tianjin Pharm,2002,14(2):12
[8] 王晶,黄荣清,肖炳坤,等.药物多晶型研究中的分析技术[J].药物分析杂志,2007,27(3):464 WANG J,HUANG RQ,XIAO BK,et al.Analytical techniques adopted in the research of drug polymorphism[J].Chin J Pharm Anal,2007,27(3):464
[9] 曾凡彬.影响难溶性药物口服固体制剂溶出特性的理化因素-晶型和粒度[J].中国新药杂志,2002,11(7):507 ZENG FB.Physicochemical factors affecting dissolution characteristics of insoluble drug oral solid preparations-crystalline form and particle size[J].Chin J New Drugs,2002,11(7):507
[10] 张庆文,许艳艳,时惠麟.阿立哌唑晶型及其制备方法:中国专利,200510026517.9[P].2006-05-17 ZHANG QW,XU YY,SHI HL.Crystal Form of Aripiprazole and Its Preparation Method:China,200510026517.9[P].2006-05-17
[11] 曲峰,李岚,利虔,等.阿立哌唑的晶型:中国专利,200410030751.4[P].2005-10-05 QU F,LI L,LI Q,et al.Crystal Form of Aripiprazole:China,200410030751.4[P].2005-10-05
[12] 阿伦希姆·J,多利茨基·B·Z,卢夫吉克·E,等.阿立哌唑晶型的制备方法:中国专利,200480041610.0[P].2007-02-14 ARENHEIM J,DOLITSKY BZ,LUFJIK E,et al.Preparation of Aripiprazole Crystal Form:China,200480041610.0[P].2007-02-14
[13] 崔秀珍,吴成秀,秦庸硕,等.制备无水阿立哌唑晶型Ⅱ的方法:中国专利,201280016853.3[P].2012-03-30 CUI XZ,WU CX,QIN YS,et al.Preparation of Anhydrous Aripiprazole Crystal Type Ⅱ:China,201280016853.3[P].2012-03-30
[14] 埃特玛·GJB,威瑟姆·RJH,卡尔莫阿·F,等.制备结晶阿立哌唑的方法:中国专利,201210046400.7[P].2005-11-17 ETMA GJB,WESSEM RJH,KARMOA F,et al.Methods for Preparation of Crystalline Aripidazole:China,201210046400.7[P].2005-11-17
[15] 诸葛明,邢乃果,张道林,等.阿立哌唑的新晶型及其制备方法:中国专利,200410079381.3[P].2004-10-14 ZHUGE M,XING NG,ZHANG DL,et al.A New Crystal Form of Aripiprazole and Its Preparation Method:China,200410079381.3[P].2004-10-14
[16] 中华人民共和国药典2015年版.二部[S].2015:541 ChP 2015.Vol Ⅱ[S].2015:541
[17] 翁水旺,郑丽清.药物溶出度试验的应用和进展[J].中国医院药学杂志,2003,23(4):240 WENG SW,ZHENG LQ.Application and progress of drug dissolution test[J].Chin Hosp Pharm J,2003,23(4):240
[18] 阳长明,侯世祥.药物溶出度研究进展[J].中成药,2000,22(7):511 YANG CM,HOU SX.Research progress in drug dissolution[J].Chin Tradit Pat Med,2000,22(7):511